Opening Session and Congress Overview
Emerging Technologies in Cell Engineering: Development of Novel Cell Therapies
Novel Strategies To Improve Cord Blood Transplant Outcomes in Adults with Hematologic Malignancies
Tresosulfan-based Conditioning Regimens for Malignant Disease
Contract Language and Release of Products from Family Banking Programs
Establishment of a Cellular Therapy Product Stability Program: Summarizing the Work of the AABB-ISCT Joint Working Group
Life Sciences: Combining Reproductive and Stem Cell Services
The Use of Umbilical Cord Blood for Autologous Transfusions in Neonatal Cardiac Surgery
Cord Blood as Adoptive Immunotherapy for Refractory AML: Bridge to Transplant
Learning from the Past
Lifetime Achievement Award and Keynote Lecture: How To Enhance the Efficacy of Cord Blood Hematopoietic Cell Transplantation
Impact of HLA and Haplotype Matching on Outcomes after Single-Unit Umbilical Cord Blood Transplantation
Selection Criteria of Double Cord Blood Transplants
Consenting for Cord Blood Donation in the Modern Era of Commercialization
Adult Frailty Trial
Consolidation and Globalization of Cord Blood
Cord Blood-Derived Mesenchymal Cells for Foot Ulcers
Striking the Right Cord: an Industry Perspective
Why I Am Not Doing Cord Blood Transplants: from the Adult HCT Transplant Program Perspective
Overview of Cellular Immunotherapies and the Importance of Cord Blood as a Source of Starting Material for Immunotherapies
East Mediterranean Blood and Marrow Transplant – EBMT
World Marrow Donor Association-NetCord (WMDA-NetCord)
Clinical Trials Design: Real-World Evidence and Case Histories
Panel Discussion: The Best Way To Maintain an Appropriate Inventory
Choosing Between Alternative Donors: the Pediatric HCT Transplant Program Perspective
Cord Blood Transplantation for Non-Malignant Diseases Using a Serotherapy-Free Conditioning Regimen (with Immune Reconstitution Data )
Cord Blood Transplantation for b-thal: Taiwan Study
Human Cytokine-Induced Memory-Like Natural Killer Cells and Clinical Applications
Center for International Blood and Marrow Transplant Research (CIBMTR)
Two Bayesian Clinical Trial Designs for Precision Medicine in Oncology
Novel Ideas in Cord Blood Selection
Oral Abstracts and Best Abstract Awards
Point/Counterpoint Debate
Eurocord
Japan Society for Hematopoietic Cell Transplantation/Japanese Data Center for Hematopoietic Cell Transplantation (JSHCT/JDCHCT)
How To Design a Multi-Center Trial with Little Funding and No Involvement of BMT/CTN
Strategies To Ensure that New Public Units Meet Clinical Needs without Compromising Bank Sustainability
FDA's Approach to Products Derived from Cord Blood
Ethical and Regulatory Issues (Panel Discussion)
Defining Real World Release Specifications for Use of Cord Blood and Cord Tissue-Derived Products in the Clinic
Ethical Responsibilities of Key Stakeholders In Cord Blood Banking and Use
Impact of Zika Virus on Public Cord Blood Banking: Reconciling CDC Travel Warnings with Donor Screening
What Is the Role, if Any, of Expanded Access Protocols in Supporting Applications for Licensure of Novel Cell Therapy Products
Accelerating the Uptake of Cord Blood-Derived Therapies by Improving Quality through Manufacturing Automation
Product Release Tests and Release Criteria (Interactive Panel)
Characterization of MSCs from Multiple Tissue Sources
This presentation is not available, by agreement with the author.
Characterization of MSCs from Multiple Tissue Sources
This presentation is not available, by agreement with the author.
Cord Blood MSC Manufacturing and Clinical Applications
This presentation is not available, by agreement with the author.
Cord Blood MSC Manufacturing and Clinical Applications
This presentation is not available, by agreement with the author.
Cord Blood Regulatory T-Cells: from Bench to Bedside
This presentation is not available, by agreement with the author.
Cord Blood Regulatory T-Cells: from Bench to Bedside
This presentation is not available, by agreement with the author.
Cord Blood Therapies, a Game Changer for Children with Brain Disorders
This presentation is not available, by agreement with the author.
Cord Blood Therapies, a Game Changer for Children with Brain Disorders
This presentation is not available, by agreement with the author.
NYSCF: Partnering with Industry and Academia to Accelerate Cures
This presentation is not available, by agreement with the author.
NYSCF: Partnering with Industry and Academia to Accelerate Cures
This presentation is not available, by agreement with the author.
Mechanisms of Immune Evasion and Relapse after HCT
This presentation is not available, by agreement with the author.
Mechanisms of Immune Evasion and Relapse after HCT
This presentation is not available, by agreement with the author.
Comparison of Haplo vs. Cord Blood HCT in Pediatrics
This presentation is not available, by agreement with the author.
Comparison of Haplo vs. Cord Blood HCT in Pediatrics
This presentation is not available, by agreement with the author.
Novel Conditioning Regimen: Antibody (c-KIT) Conditioning for Non-Malignant Disease
This presentation is not available, by agreement with the author.
Novel Conditioning Regimen: Antibody (c-KIT) Conditioning for Non-Malignant Disease
This presentation is not available, by agreement with the author.
The Role of Cord Blood Monocytes in Modulating Non-Malignant Diseases
This presentation is not available, by agreement with the author.
The Role of Cord Blood Monocytes in Modulating Non-Malignant Diseases
This presentation is not available, by agreement with the author.
Leveraging Natural Killer Cell Immunotherapy through Cytokine-Bearing Antigen-Specific TriKE Molecules
This presentation is not available, by agreement with the author.
Leveraging Natural Killer Cell Immunotherapy through Cytokine-Bearing Antigen-Specific TriKE Molecules
This presentation is not available, by agreement with the author.
Clinical Trials Design: Real-World Evidence and Case Histories
This presentation is not available, by agreement with the author.
Clinical Trials Design: Real-World Evidence and Case Histories
This presentation is not available, by agreement with the author.
Development of a Therapeutic NK Cell Product Generated from Cord Blood CD34+ Cells Expanded on Notch Ligand
This presentation is not available, by agreement with the author.
Development of a Therapeutic NK Cell Product Generated from Cord Blood CD34+ Cells Expanded on Notch Ligand
This presentation is not available, by agreement with the author.